Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892960 | 0.91 | MMP8 (0.61) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL3123872 | 0.90 | MMP8 (0.54) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL13752142 | 0.90 | MMP8 (0.54) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL19210801 | 0.89 | MMP8 (0.52) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL5085947 | 0.88 | MMP8 (0.55) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL15016003 | 0.86 | MMP8 (0.56) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL27622664 | 0.86 | MMP8 (0.56) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL14753735 | 0.85 | MMP8 (0.52) | MMP8L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL5324827 | 0.85 | ESR1 (0.47) | MMP8KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5143568 | 0.85 | MMP8 (0.55) | MMP8L3MBTL1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2023-08-10 | — | — | US | disclosed |
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | BIOPHARMA CREDIT PLC (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11148997-B2 | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | INSMED INCORPORATED (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210276940-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10995055-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2021-05-04 | — | — | US | disclosed |
| US-20190337888-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | BIOPHARMA CREDIT PLC (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20190248731-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20160256425-A1 | Prostacyclin Compounds, Compositions and Methods of use Thereof | BIOPHARMA CREDIT PLC (GB) | 2016-09-08 | — | — | US | disclosed |
| US-9255064-B2 | Prostacyclin compounds, compositions and methods of use thereof | INSMED INCORPORATED (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150175529-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2015-06-25 | — | — | US | disclosed |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | BIOPHARMA CREDIT PLC (GB) | 2015-05-28 | — | — | US | disclosed |
| CN-104412441-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2015-03-11 | — | — | CN | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| EP-0214639-B1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | G.D. Searle & Co. (US) | 1990-06-13 | — | — | EP | disclosed |
| EP-0214639-A2 | Hydroxamic acid based collagenase inhibitors | G.D. Searle & Co. (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250051-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, THOP1, PTGIR | MMP8 399/4885L3MBTL1 890/4885LMNA 1018/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | MMP8 142/4885L3MBTL1 888/4885LMNA 2110/4885 |
| US-20190248731-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGER3, PTGER1 | MMP8 714/4885L3MBTL1 1660/4885LMNA 766/4885 |
| US-20210276940-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, PTGER1, PTGIR | MMP8 904/4885L3MBTL1 817/4885LMNA 704/4885 |
| US-11148997-B2 | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | PTGIS, PTGER1, PTGIR | MMP8 904/4885L3MBTL1 817/4885LMNA 704/4885 |
| US-20150148414-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | MMP8 142/4885L3MBTL1 888/4885LMNA 2110/4885 |
| US-20190337888-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, THOP1, PTGIR | MMP8 417/4885L3MBTL1 909/4885LMNA 975/4885 |
| US-10995055-B2 | Prostacyclin compounds, compositions and methods of use thereof | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
| US-11795135-B2 | Prostacyclin compounds, compositions and methods of use thereof | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
| US-20160256425-A1 | Prostacyclin Compounds, Compositions and Methods of use Thereof | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
| US-20150175529-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | PTGIS, PTGIR, PTGER1 | MMP8 706/4885L3MBTL1 1564/4885LMNA 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.